+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antisense & RNAi Therapeutics Global Market Report 2022: By Technology, By Route, By Indication

  • PDF Icon

    Report

  • 175 Pages
  • March 2022
  • Region: Global
  • The Business Research Company
  • ID: 5553743
Antisense & RNAi Therapeutics Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global antisense & RNAi therapeutics market.



This report focuses on antisense & RNAi therapeutics market which is experiencing strong growth. The report gives a guide to the antisense & RNAi therapeutics market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase


  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates
  • Create regional and country strategies on the basis of local data and analysis
  • Identify growth segments for investment
  • Outperform competitors using forecast data and the drivers and trends shaping the market
  • Understand customers based on the latest market research findings
  • Benchmark performance against key competitors
  • Utilize the relationships between key data sets for superior strategizing
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for the antisense & RNAi therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Antisense & RNAi Therapeutics market global report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider antisense & RNAi therapeutics market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the Covid 19 virus and forecasting its growth
  • Market segmentations break down market into sub markets
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of Covid 19 for all regions, key developed countries and major emerging markets
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers
  • The antisense & RNAi therapeutics market section of the report gives context. It compares the antisense & RNAi therapeutics market with other segments of the antisense & RNAi therapeutics market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, antisense & RNAi therapeutics indicators comparison

Scope


Markets Covered:


1) By Technology: RNA Interference; Antisense RNA
2) By Route of Administration: Pulmonary Delivery; Intravenous Injections; Intra-dermal Injections; Intraperitoneal Injections; Topical Delivery; Other Delivery Methods
3) By Indication: Oncology; Cardiovascular Diseases (CVDs); Respiratory Disorders; Neurological Disorders; Infectious Diseases; Other

Companies Mentioned:Alnylam Pharmaceuticals; Benitec Biopharma Ltd.; Gene Signal; GlaxoSmithKline Plc; Ionis Pharmaceuticals

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Frequently Asked Questions about the Global Antisense & RNAI Therapeutics Market

What is the estimated value of the Global Antisense & RNAI Therapeutics Market?

The Global Antisense & RNAI Therapeutics Market was estimated to be valued at $1.4 billion in 2022.

What is the growth rate of the Global Antisense & RNAI Therapeutics Market?

The growth rate of the Global Antisense & RNAI Therapeutics Market is 10.8%, with an estimated value of $2.1 billion by 2026.

What is the forecasted size of the Global Antisense & RNAI Therapeutics Market?

The Global Antisense & RNAI Therapeutics Market is estimated to be worth $2.1 billion by 2026.

Who are the key companies in the Global Antisense & RNAI Therapeutics Market?

Key companies in the Global Antisense & RNAI Therapeutics Market include Alnylam Pharmaceuticals, Benitec Biopharma Ltd., Gene Signal, GlaxoSmithKline plc., Ionis Pharmaceuticals, Marina Biosciences, Quark Pharmaceuticals, Sanofi S.A and Antisense Therapeutics Ltd..

Table of Contents

1. Executive Summary2. Antisense & RNAi Therapeutics Market Characteristics3. Antisense & RNAi Therapeutics Market Trends And Strategies4. Impact Of COVID-19 On Antisense & RNAi Therapeutics
5. Antisense & RNAi Therapeutics Market Size And Growth
5.1. Global Antisense & RNAi Therapeutics Historic Market, 2016-2021, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Antisense & RNAi Therapeutics Forecast Market, 2021-2026F, 2031F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Antisense & RNAi Therapeutics Market Segmentation
6.1. Global Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • RNA Interference
  • Antisense RNA
6.2. Global Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Pulmonary Delivery
  • Intravenous Injections
  • Intra-dermal Injections
  • Intraperitoneal Injections
  • Topical Delivery
  • Other Delivery Methods
6.3. Global Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Oncology
  • Cardiovascular Diseases (CVDs)
  • Respiratory Disorders
  • Neurological Disorders
  • Infectious Diseases
  • Other

7. Antisense & RNAi Therapeutics Market Regional And Country Analysis
7.1. Global Antisense & RNAi Therapeutics Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7.2. Global Antisense & RNAi Therapeutics Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8. Asia-Pacific Antisense & RNAi Therapeutics Market
8.1. Asia-Pacific Antisense & RNAi Therapeutics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8.3. Asia-Pacific Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
9. China Antisense & RNAi Therapeutics Market
9.1. China Antisense & RNAi Therapeutics Market Overview
9.2. China Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
9.3. China Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
10. India Antisense & RNAi Therapeutics Market
10.1. India Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
10.2. India Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11. Japan Antisense & RNAi Therapeutics Market
11.1. Japan Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11.2. Japan Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12. Australia Antisense & RNAi Therapeutics Market
12.1. Australia Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12.2. Australia Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13. Indonesia Antisense & RNAi Therapeutics Market
13.1. Indonesia Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13.2. Indonesia Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14. South Korea Antisense & RNAi Therapeutics Market
14.1. South Korea Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14.2. South Korea Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15. Western Europe Antisense & RNAi Therapeutics Market
15.1. Western Europe Antisense & RNAi Therapeutics Market Overview
15.2. Western Europe Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15.3. Western Europe Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16. UK Antisense & RNAi Therapeutics Market
16.1. UK Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16.2. UK Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17. Germany Antisense & RNAi Therapeutics Market
17.1. Germany Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17.2. Germany Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18. France Antisense & RNAi Therapeutics Market
18.4. France Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18.5. France Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19. Eastern Europe Antisense & RNAi Therapeutics Market
19.1. Eastern Europe Antisense & RNAi Therapeutics Market Overview
19.2. Eastern Europe Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19.3. Eastern Europe Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20. Russia Antisense & RNAi Therapeutics Market
20.1. Russia Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20.2. Russia Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21. North America Antisense & RNAi Therapeutics Market
21.1. North America Antisense & RNAi Therapeutics Market Overview
21.2. North America Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21.3. North America Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22. USA Antisense & RNAi Therapeutics Market
22.1. USA Antisense & RNAi Therapeutics Market Overview
22.2. USA Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22.3. USA Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23. South America Antisense & RNAi Therapeutics Market
23.1. South America Antisense & RNAi Therapeutics Market Overview
23.2. South America Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23.3. South America Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24. Brazil Antisense & RNAi Therapeutics Market
24.1. Brazil Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24.2. Brazil Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25. Middle East Antisense & RNAi Therapeutics Market
25.1. Middle East Antisense & RNAi Therapeutics Market Overview
25.2. Middle East Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25.3. Middle East Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26. Africa Antisense & RNAi Therapeutics Market
26.1. Africa Antisense & RNAi Therapeutics Market Overview
26.2. Africa Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26.3. Africa Antisense & RNAi Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
27. Antisense & RNAi Therapeutics Market Competitive Landscape And Company Profiles
27.1. Antisense & RNAi Therapeutics Market Competitive Landscape
27.2. Antisense & RNAi Therapeutics Market Company Profiles
27.2.1. Alnylam Pharmaceuticals
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Benitec Biopharma Ltd.
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Gene Signal
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. GlaxoSmithKline Plc
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Ionis Pharmaceuticals
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Antisense & RNAi Therapeutics Pipeline Analysis29. Key Mergers And Acquisitions In The Antisense & RNAi Therapeutics Market30. Antisense & RNAi Therapeutics Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer

Executive Summary

Major players in the antisense & RNAi therapeutics market are Alnylam Pharmaceuticals, Benitec Biopharma Ltd., Gene Signal, GlaxoSmithKline Plc, Ionis Pharmaceuticals, Marina Biosciences, Quark Pharmaceuticals, Sanofi S.A, Acuitas Therapeutics and Antisense Therapeutics Ltd.

The global antisense & RNAI therapeutics market is expected to grow from $1.32 billion in 2021 to $1.42 billion in 2022 at a compound annual growth rate (CAGR) of 8%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $2.14 billion in 2026 at a CAGR of 10.8%.

The antisense & RNAi therapeutics market consists of sales of antisense & RNAi therapeutics products and related services by entities (organizations, sole traders and partnerships) that develop antisense & RNAi therapeutics to treat various diseases. RNA interference (RNAi)-based and RNA-based antisense oligonucleotide therapies are advanced methods used for the treatment of various respiratory diseases including chronic obstructive pulmonary disease (COPD) and asthma. In addition to this, antisense & RNAi therapeutics finds its application in curing cancer, infectious diseases, cardiovascular diseases, and genetic disorders.

The main technologies of antisense & RNAi therapeutics are RNA interference, antisense RNA. RNA interference is a conserved biological response to double-stranded RNA that mediates resistance to both endogenous parasitic and exogenous pathogenic nucleic acids and regulates protein-coding gene expression. The various route of administration include pulmonary delivery, intravenous injections, intra-dermal injections, intraperitoneal injections, topical delivery, other delivery methods that are used for the indication of oncology, cardiovascular diseases (CVDs), respiratory disorders, neurological disorders, infectious diseases, other.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The rising prevalence of coronary artery diseases, neurodegenerative disorders, and infectious diseases is projected to contribute to the demand for the antisense & RNAi therapeutics market. Gene suppression approaches including RNA interference and antisense oligonucleotides are used for the treatment of various neurodegenerative conditions by repairing mutant genes. According to the National Institute of Environmental Health Sciences, Alzheimer’s disease and Parkinson’s disease is the most common neurodegenerative diseases affecting millions of people globally. In the USA, around 930,000 people had Parkinson’s disease by the end of 2020. Furthermore, according to the World Health Organization (WHO), infectious diseases are a major concern and dominated the WHO’s list of 2019 health threats ranging from various climate change issues to inadequate healthcare facilities. Hence, the growing prevalence of several neurodegenerative diseases and infectious diseases is expected to drive the growth of the antisense & RNAi therapeutics market.

The high cost of RNA interference-based drugs is expected to act as a major restraint for the growth of the antisense & RNAi therapeutics market in the future. For instance, according to Future Medicine, the price of Onpattro is approximately $450,000 per year. Onpattro (patisaran) is the RNA interference-based drug used for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Stringent regulations, long product approval process, high development cost, and a comparably small number of patients are few factors leading to the high cost of RNA interference drugs, which is expected to hinder the antisense & RNAi therapeutics’ market growth in upcoming years.

Major companies operating in the antisense & RNAi therapeutics market are undertaking strategic initiatives such as collaborations and partnerships for product innovation to sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as with academic and research institutions in this market by way of partnerships, and in or out-licensing deals. This trend has been increasing over recent years. For instance, in August 2020, Blackstone Life Sciences, a global investment company, and Alnylam Pharmaceuticals, Inc., an RNAi therapeutics company, announced the closing of a $2 billion strategic financing collaboration to accelerate the advancement and development of RNAi therapeutics. Under the agreement, Alnylam Pharmaceuticals, Inc. will receive $150 million from Blackstone Life Sciences for the development of vutrisiran and ALN-AGT, Alnylam’s cardiometabolic disease programs. In 2020, Aro Biotherapeutics Company has announced a licensing and collaboration agreement with Ionis Pharmaceuticals, Inc., the market leader in RNA-targeted therapeutics, under which Ionis will use Aro's CENTYRINTM technology to develop targeted cell- and tissue-specific delivery of antisense oligonucleotides (ASOs).

In November 2019, Novartis International AG, a Switzerland-based pharmaceutical company acquired The Medicines Company, a US-based biopharmaceutical company, for $9.7 million. With the acquisition of The Medicines Company, Novartis International AG plans to enter RNA therapeutics by acquiring its last stage RNA interference drug designed for protection against cardiovascular diseases in twice-yearly shorts. The drug has met the primary endpoint in the three phases of clinical trials and is approved for the treatment of cardiovascular diseases in the USA in 2019 and the EU in early 2020. The Medicines Company is a US-based company focused on the development of RNA drug inclisiran that is used in the treatment of renal impairment and cardiovascular diseases.

The countries covered in the antisense & RNAi therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Alnylam Pharmaceuticals
  • Benitec Biopharma Ltd.
  • Gene Signal
  • GlaxoSmithKline plc.
  • Ionis Pharmaceuticals
  • Marina Biosciences
  • Quark Pharmaceuticals
  • Sanofi S.A
  • Acuitas Therapeutics
  • Antisense Therapeutics Ltd.
  • Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals)
  • Bio-Path Holdings inc.
  • Calando Pharmaceuticals
  • Dicerna Pharmaceuticals
  • Enzon Pharmaceuticals inc.
  • Gradalis
  • iCo Therapeutics
  • miRagen Therapeutics
  • Olix Pharmaceuticals
  • OncoGeneX Pharmaceuticals
  • Lorus Therapeutics (Aptose Biosciences)
  • Regulus Therapeutics
  • Rexahn Pharmaceuticals
  • Rxi Pharmaceuticals
  • Santaris Pharma A/S (Roche)
  • Sarepta Therapeutics
  • Silence Therapeutics plc.
  • Sirnaomics inc.
  • Tekmira Pharmaceuticals
  • Cenix BioScience
  • Sirnaomics

Methodology

Loading
LOADING...